OCON Therapeutics Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
34
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$10M
- Investors
-
17
OCON Therapeutics General Information
Description
Developer of an intrauterine drug-delivery technology intended for the treatment of uterus-based conditions. The company's product is made from a super-elastic alloy and is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas or fibroids, and infertility, providing clinicians with technology to improve and impact women's health and quality of life.
Contact Information
Website
www.oconmed.comCorporate Office
- Hamiktso'ot Boulevard 14
- Modiin 7178095
- Israel
Corporate Office
- Hamiktso'ot Boulevard 14
- Modiin 7178095
- Israel
OCON Therapeutics Timeline
OCON Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC | 24-Jun-2024 | $10M | Completed | Generating Revenue | ||
| 11. Equity Crowdfunding | Completed | Generating Revenue | ||||
| 10. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 9. Accelerator/Incubator | 10-May-2022 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 20-Oct-2021 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B) | 21-Jan-2021 | Cancelled | Generating Revenue | |||
| 6. Later Stage VC (Series A) | 31-Dec-2020 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 24-Jun-2020 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 01-Jan-2016 | $3M | $8.01M | Completed | Generating Revenue | |
| 3. Early Stage VC | 01-Jan-2014 | $3M | $5.01M | Completed | Generating Revenue |
OCON Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred B2 | ||||||||
| Preferred E | ||||||||
| Preferred D | ||||||||
| Preferred C1 | ||||||||
| Preferred B1 | 55,000 | $28.14 | $28.14 | 1x | $28.14 | 13.71% | ||
| Preferred A | 275,000 | $12.03 | $12.03 | 1x | $12.03 | 10.87% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
OCON Therapeutics Comparisons
Industry
Financing
Details
OCON Therapeutics Competitors (6)
One of OCON Therapeutics’s 6 competitors is 3Daughters, a Venture Capital-Backed company based in Mansfield, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 3Daughters | Venture Capital-Backed | Mansfield, MA | ||||
| Viramal | Venture Capital-Backed | London, United Kingdom | ||||
| Hologic | Formerly VC-backed | Marlborough, MA | ||||
| Bayer | Corporation | Leverkusen, Germany | ||||
| Organon & Co. | Private Debt Financed | Jersey City, NJ |
OCON Therapeutics Patents
OCON Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4213775-A1 | Device positionable in the uterine cavity and method of treatment thereof | Pending | 21-Sep-2020 | ||
| US-11642502-B2 | Device positionable in the uterine cavity and method of treatment thereof | Active | 21-Sep-2020 | ||
| US-20220134069-A1 | Device positionable in the uterine cavity and method of treatment thereof | Active | 21-Sep-2020 | ||
| US-20230338720-A1 | Device positionable in the uterine cavity and method of treatment thereof | Active | 21-Sep-2020 | ||
| US-12161829-B2 | Device positionable in the uterine cavity and method of treatment thereof | Active | 21-Sep-2020 | A61M31/002 |
OCON Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
OCON Therapeutics Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eczacıbaşı Momentum | Corporate Venture Capital | |||
| Exerte Partners | Family Office | Minority | ||
| Features Capital | Venture Capital | Minority | ||
| The World Economic Forum | Accelerator/Incubator | |||
| Impact Assets | Impact Investing | Minority |
OCON Therapeutics FAQs
-
When was OCON Therapeutics founded?
OCON Therapeutics was founded in 2011.
-
Where is OCON Therapeutics headquartered?
OCON Therapeutics is headquartered in Modiin, Israel.
-
What is the size of OCON Therapeutics?
OCON Therapeutics has 34 total employees.
-
What industry is OCON Therapeutics in?
OCON Therapeutics’s primary industry is Drug Delivery.
-
Is OCON Therapeutics a private or public company?
OCON Therapeutics is a Private company.
-
What is OCON Therapeutics’s current revenue?
The current revenue for OCON Therapeutics is .
-
How much funding has OCON Therapeutics raised over time?
OCON Therapeutics has raised $22.5M.
-
Who are OCON Therapeutics’s investors?
Eczacıbaşı Momentum, Exerte Partners, Features Capital, The World Economic Forum, and Impact Assets are 5 of 17 investors who have invested in OCON Therapeutics.
-
Who are OCON Therapeutics’s competitors?
3Daughters, Viramal, Hologic, Bayer, and Organon & Co. are some of the 6 competitors of OCON Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
